AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31268555 — intervention group
Group type: EXPERIMENTAL
Intervention: Staccato alprazolam 2.0 mg
Number of subjects: 5
Study 31268555 — intervention group
Group type: COMPARATOR
Intervention: Staccato placebo
Number of subjects: 5
Study 28718828 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporised nicotine products (VNPs) with up to 12 weeks’ supply of nicotine e‐liquid
Number of subjects: 30
Study 28718828 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporised nicotine products (VNPs)
Number of subjects: 30
Study 26024532 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision model (n = 219)
Number of subjects: 439
Study 26024532 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 220)
Number of subjects: 439
Study 23559064 — intervention group
Group type: EXPERIMENTAL
Intervention: active rTMS
Number of subjects: 22
Study 23559064 — intervention group
Group type: COMPARATOR
Intervention: sham rTMS
Number of subjects: 22
Study 21121978 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurts containing Lactobacillus plantarum strains and Lactobacillus casei strain
Number of subjects: 62
Study 21121978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota
Number of subjects: 62
Study 21121978 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CBS125632
Number of subjects: 62
Study 21121978 — intervention group
Group type: COMPARATOR
Intervention: Placebo yoghurt
Number of subjects: 62
Study 19814793 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 49
Study 19814793 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 16411999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap repair with polyglactin (Vicryl)
Number of subjects: 150
Study 16411999 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end repair with polyglactin (Vicryl)
Number of subjects: 150
Study 16411999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlap repair with polydioxanone (PDS)
Number of subjects: 150
Study 16411999 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end repair with PDS
Number of subjects: 150
Study 16411999 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study 15223223 — intervention group
Group type: COMPARATOR
Intervention: Maternal diabetes
Number of subjects: 56492
Study 15223223 — intervention group
Group type: COMPARATOR
Intervention: Paternal diabetes
Number of subjects: 56492
Study 15223223 — intervention group
Group type: COMPARATOR
Intervention: Bilineal parental diabetes
Number of subjects: 56492
Study 15223223 — intervention group
Group type: COMPARATOR
Intervention: No parental diabetes
Number of subjects: 56492
Study 11504004 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted word presentation interval for long and short words
Number of subjects: 0
Study 11504004 — intervention group
Group type: COMPARATOR
Intervention: Standard word presentation interval
Number of subjects: 0
Study 9257202 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC premedication and halothane induction
Number of subjects: 62
Study 9257202 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC premedication and propofol induction
Number of subjects: 62
Study 9257202 — intervention group
Group type: COMPARATOR
Intervention: Placebo premedication and halothane induction
Number of subjects: 62
Study 9257202 — intervention group
Group type: COMPARATOR
Intervention: Placebo premedication and propofol induction
Number of subjects: 62
Study 8490981 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol alone
Number of subjects: 70
Study 8490981 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol + penicillin
Number of subjects: 70
Study 3491791 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin and neomycin
Number of subjects: 105
Study 3491791 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMZ and colistin
Number of subjects: 105
Study 29300971 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic genicular nerve block
Number of subjects: 54
Study 29300971 — intervention group
Group type: COMPARATOR
Intervention: No block
Number of subjects: 54
Study 27437716 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominopelvic training by virtual reality (APT_VR)
Number of subjects: 60
Study 27437716 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training using a gym ball (PFMT_GB)
Number of subjects: 60
Study 24079396 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery-based Brain Computer Interface (MI-based BCI) training
Number of subjects: 8
Study 24079396 — intervention group
Group type: COMPARATOR
Intervention: Functional Electrical Stimulation (FES) treatment
Number of subjects: 8
Study 21800180 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational training immediately (Immediate)
Number of subjects: 0
Study 21800180 — intervention group
Group type: COMPARATOR
Intervention: Vocational training delayed (Delayed)
Number of subjects: 0
Study 21800180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Immediate and Delayed groups
Number of subjects: 0
Study 20837948 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (control arm)
Number of subjects: 90
Study 20837948 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemoradiotherapy (CRT arm)
Number of subjects: 90
Study 18270586 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn resuscitation training (NRT)
Number of subjects: 83
Study 18270586 — intervention group
Group type: COMPARATOR
Intervention: Control group (late training)
Number of subjects: 83
Study 16160572 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel applied
Number of subjects: 20
Study 16160572 — intervention group
Group type: COMPARATOR
Intervention: Alloplastic graft material reconstituted with blood
Number of subjects: 20
Study 12834649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatments (CBT)
Number of subjects: 435
Study 12834649 — intervention group
Group type: COMPARATOR
Intervention: History of major depressive disorder (MDD)
Number of subjects: 435
Study 12834649 — intervention group
Group type: COMPARATOR
Intervention: History of alcohol dependence (AD)
Number of subjects: 435
Study 12834649 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analyses
Number of subjects: 435
Study 10825372 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone administration
Number of subjects: 6
Study 8878385 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus)
Number of subjects: 92
Study 1996621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol infusion (10 mg/h) after pretreatment with dexamethasone (4 mg/day) for 4 or 6 days
Number of subjects: 18
Study 1996621 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg/day) for 4 or 6 days
Number of subjects: 18
Study 1996621 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (200 mg, at 0800 and 1700 h before experimental nights)
Number of subjects: 18
Study 1996621 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 18
Study 6324934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) 20 mg/m2 daily for the entire treatment duration.
Number of subjects: 79
Study 6324934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of Tamoxifen (TAM) 20 mg/m2 daily for 15 days followed by Medroxyprogesterone acetate 350 mg/m2 daily for the next 15 days.
Number of subjects: 79
Study 6324934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of Tamoxifen (TAM) and Medroxyprogesterone acetate.
Number of subjects: 79
Study 30840307 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine (Group K1)
Number of subjects: 60
Study 30840307 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg ketamine (Group K1.5)
Number of subjects: 60
Study 30840307 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg ketamine (Group K2)
Number of subjects: 60
Study 29394975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin combination therapy
Number of subjects: 196
Study 25261491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut-out orthosis
Number of subjects: 46
Study 25261491 — intervention group
Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 46
Study 24578358 — intervention group
Group type: COMPARATOR
Intervention: Moderate alcohol consumption
Number of subjects: 11000
Study 24578358 — intervention group
Group type: COMPARATOR
Intervention: Wine consumption
Number of subjects: 11000
Study 24578358 — intervention group
Group type: COMPARATOR
Intervention: Heavy alcohol consumption
Number of subjects: 11000
Study 22997785 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint heat-sensitive moxibustion, 50 treatments over 3 months, 30 to 90 minutes each treatment.
Number of subjects: 64
Study 22997785 — intervention group
Group type: COMPARATOR
Intervention: Seretide inhaler, one inhalation twice per day for 3 months.
Number of subjects: 64
Study 20444448 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated pins (HA group)
Number of subjects: 40
Study 20444448 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel pins (steel group)
Number of subjects: 40
Study 17854448 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based treatment designed to accelerate cerebellar development
Number of subjects: 0
Study 17854448 — intervention group
Group type: COMPARATOR
Intervention: Control data
Number of subjects: 0
Study 15858811 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized Intermittent Mandatory Ventilation (SIMV)
Number of subjects: 18
Study 15858811 — intervention group
Group type: COMPARATOR
Intervention: Conventional Intermittent Mandatory Ventilation (IMV)
Number of subjects: 18
Study 12539003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high dose)
Number of subjects: 60
Study 12539003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (low dose)
Number of subjects: 60
Study 12539003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12539003 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (both doses)
Number of subjects: 60
Study 10759824 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodessication
Number of subjects: 0
Study 10759824 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser
Number of subjects: 0
Study 8884643 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% tetracycline fiber
Number of subjects: 52
Study 8884643 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minocycline gel
Number of subjects: 52
Study 8884643 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% metronidazole gel
Number of subjects: 52
Study 8884643 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 52
Study 1852793 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (40-80 mg/d)
Number of subjects: 65
Study 1852793 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (50-150 mg/d)
Number of subjects: 65
Study 6358700 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical fitness program
Number of subjects: 0
Study 6358700 — intervention group
Group type: COMPARATOR
Intervention: Customary organized activities
Number of subjects: 0
Study 31858234 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 426
Study 31858234 — intervention group
Group type: COMPARATOR
Intervention: No hormone therapy (No HT)
Number of subjects: 426
Study 30453379 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 G Flex needle
Number of subjects: 125
Study 30453379 — intervention group
Group type: COMPARATOR
Intervention: 22 G needle
Number of subjects: 125
Study 28216550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (F)
Number of subjects: 7
Study 28216550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (S)
Number of subjects: 7
Study 28216550 — intervention group
Group type: COMPARATOR
Intervention: Glucose (G)
Number of subjects: 7
Study 28216550 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 7
Study 28216550 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose + Fructose (C)
Number of subjects: 7
Study 26390724 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) 6 mg/m2
Number of subjects: 1064
Study 26390724 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MePRED) 60 mg/m2
Number of subjects: 1064
Study 26390724 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) in children younger than 14 years
Number of subjects: 1064
Study 26390724 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (MePRED) in adolescents aged 14-18 years
Number of subjects: 1064
Study 24100259 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline administration
Number of subjects: 0
Study 21883954 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil ODT 10 mg
Number of subjects: 89
Study 21883954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 19214890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose/mannitol (L/M) ratio
Number of subjects: 47
Study 19214890 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharose excretion
Number of subjects: 47
Study 19214890 — intervention group
Group type: EXPERIMENTAL
Intervention: AGA-IgA
Number of subjects: 47
Study 19214890 — intervention group
Group type: EXPERIMENTAL
Intervention: AGA-IgG
Number of subjects: 47
Study 19214890 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA assay
Number of subjects: 47
Study 19214890 — intervention group
Group type: EXPERIMENTAL
Intervention: L/M ratio in group A (n = 23)
Number of subjects: 47
Study 19214890 — intervention group
Group type: EXPERIMENTAL
Intervention: EMA in group B
Number of subjects: 47
Study 17273647 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education (three two-hour meetings over three weeks)
Number of subjects: 80
Study 15272100 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) extract LI 160, 300 mg twice daily for 6 weeks
Number of subjects: 184
Study 15272100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 11384792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus aerobic exercise plus usual and customary care
Number of subjects: 1356
Study 11384792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise plus usual and customary care
Number of subjects: 1356
Study 11384792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus usual and customary care
Number of subjects: 1356
Study 11384792 — intervention group
Group type: COMPARATOR
Intervention: Usual and customary care alone
Number of subjects: 1356
Study 9100744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses viewing videotaped interviews of patients with different family structures (married mother, married with no children, divorced mother, divorced with no children, unmarried mother, unmarried with no children, remarried with spouse's children, remarried with no children)
Number of subjects: 0
Study 8491438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (50, 100, 150, or 200 mg)
Number of subjects: 42
Study 3031225 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (arm C)
Number of subjects: 288
Study 3031225 — intervention group
Group type: COMPARATOR
Intervention: Etoposide (arm B)
Number of subjects: 288
Study 3031225 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (arm A)
Number of subjects: 288
Study 3031225 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (arm C) for favorable performance status (0 + 1)
Number of subjects: 288
Study 3031225 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (arm A) for favorable performance status (0 + 1)
Number of subjects: 288
Study 3031225 — intervention group
Group type: COMPARATOR
Intervention: Etoposide (arm B) for favorable performance status (0 + 1)
Number of subjects: 288
Study 29135347 — intervention group
Group type: EXPERIMENTAL
Intervention: High relative cerebral blood volume (rCBV)
Number of subjects: 158
Study 29135347 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hypoperfusion index ratio (HIR)
Number of subjects: 158
Study 29135347 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative cerebral blood volume (rCBV)
Number of subjects: 158
Study 29135347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower relative cerebral blood volume (rCBV)
Number of subjects: 158
Study 27821093 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine pranobex
Number of subjects: 463
Study 27821093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study 24600651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL (0.3 mg/mL) recombinant human platelet-derived growth factor BB (rh-PDGF-BB) mixed with bovine or equine matrix
Number of subjects: 8
Study 24600651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mL (0.3 mg/mL) recombinant human platelet-derived growth factor BB (rh-PDGF-BB) mixed with equine matrix
Number of subjects: 8
Study 22903911 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (participants wrote about their deepest thoughts and feelings relating to their ambivalence)
Number of subjects: 40
Study 22903911 — intervention group
Group type: COMPARATOR
Intervention: Control condition (participants wrote about how they had spent their time that day or week)
Number of subjects: 40
Study 20353114 — intervention group
Group type: COMPARATOR
Intervention: Continuous wave electroacupuncture
Number of subjects: 85
Study 20353114 — intervention group
Group type: EXPERIMENTAL
Intervention: Rarefaction wave electroacupuncture
Number of subjects: 85
Study 18583287 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB with cTnT <1 ng/mL
Number of subjects: 1511
Study 18583287 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB with cTnT >=1 ng/mL
Number of subjects: 1511
Study 18583287 — intervention group
Group type: COMPARATOR
Intervention: CCAB
Number of subjects: 1511
Study 16982385 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led physical activity (TLPA) program
Number of subjects: 90
Study 16982385 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-led physical activity (SLPA) program
Number of subjects: 90
Study 16982385 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 14563343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40mg
Number of subjects: 500
Study 14563343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 10937409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital in the Home (HITH)
Number of subjects: 100
Study 10937409 — intervention group
Group type: COMPARATOR
Intervention: Hospital admission (control group)
Number of subjects: 100
Study 9014651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Ca as CaCO3, consumed between meals 5 days/week for 1 year
Number of subjects: 60
Study 9014651 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study 1569347 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin, 400 mg, single oral dose
Number of subjects: 98
Study 1569347 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP‐SMZ), 160/800 mg, twice daily for 3 days
Number of subjects: 98
Study 3902176 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg diltiazem
Number of subjects: 16
Study 3902176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3902176 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg diltiazem
Number of subjects: 16
Study 3902176 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg diltiazem
Number of subjects: 16
Study 30044935 — intervention group
Group type: EXPERIMENTAL
Intervention: Thawed plasma administration
Number of subjects: 501
Study 30044935 — intervention group
Group type: COMPARATOR
Intervention: Standard-care resuscitation
Number of subjects: 501
Study 28734146 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body diffusion-weighted MRI (WB-DWI/MRI)
Number of subjects: 161
Study 28734146 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 161
Study 26148364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinal‐iliohypogastric block with 10 ml 0.5% ropivacaine from each side
Number of subjects: 164
Study 26148364 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane block with 20 ml 0.25% ropivacaine
Number of subjects: 164
Study 26148364 — intervention group
Group type: EXPERIMENTAL
Intervention: Both blocks
Number of subjects: 164
Study 22785001 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Virtual Environment (VE)
Number of subjects: 32
Study 22785001 — intervention group
Group type: COMPARATOR
Intervention: Physical Environment (PE)
Number of subjects: 32
Study 20363905 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction-inhibiting implementation intention
Number of subjects: 0
Study 20363905 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-facilitating implementation intention
Number of subjects: 0
Study 18186265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 18186265 — intervention group
Group type: COMPARATOR
Intervention: Observation (standard of care)
Number of subjects: 0
Study 15940125 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based monitoring
Number of subjects: 300
Study 14669282 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT) after hyper-CVAD regimen; high-dose cyclophosphamide (120 mg/kg), total body irradiation, and ASCT.
Number of subjects: 33
Study 14669282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with M. D. Anderson Lymphoma Tumor Score (TS) ≤ 1 at diagnosis or transplantation.
Number of subjects: 33
Study 14669282 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with β2-microglobulin (β2m) level ≤ 3 mg/L at diagnosis or transplantation.
Number of subjects: 33
Study 10097996 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM test scores in normal children (n = 70)
Number of subjects: 70
Study 10097996 — intervention group
Group type: EXPERIMENTAL
Intervention: TOM test in young children
Number of subjects: 70